Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What is the Projected CAGR for the Spinal Muscular Atrophy Market Size from 2025 to 2034?

The market for spinal muscular atrophy has experienced swift expansion in recent times. Its growth is projected to increase from $3.53 billion in 2024 to $4.01 billion in 2025, marking a compound annual growth rate (CAGR) of 13.5%. The notable growth during the historical period is due to factors such as enhanced diagnosis and early detection efforts, an increasing occurrence of rare genetic diseases, advancements in healthcare infrastructure, support from government and regulatory bodies, and the rise in unfulfilled healthcare requirements.

Anticipated in the coming years is a swift upsurge in the market size of spinal muscular atrophy. A compound annual growth rate (CAGR) of 13.2% is forecasted, propelling the market to reach $6.59 billion by 2029. The projected growth within this period can be credited to factors like enhanced awareness and diagnosis rates, improved accessibility of treatment, rising investments in healthcare regarding rare diseases, a conducive regulatory climate, and escalating healthcare expenditure. Key trends predicted for the forecast period involve progress in oral therapies, the application of gene therapy, advancements in drug delivery technology, the incorporation of artificial intelligence in the development of SMA treatment, and gene editing technologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

What Are the Core Growth Drivers Propelling the Spinal Muscular Atrophy Market Forward?

The growth of the spinal muscular atrophy market is set to be largely influenced by the increased occurrence of uncommon genetic illnesses. These disorders, which only affect a small demographic due to gene mutations, often lead to significant, ongoing health challenges. The upsurge in the occurrence of such rare genetic conditions can be linked to enhanced diagnostic tools, a greater public consciousness, and easier access to genetic testing, which contribute to an increased number of diagnosed and reported cases. Spinal muscular atrophy (SMA) represents an example of the complexities and potential associated with understanding inherited diseases. Furthering the investigation into genetic disorders is therefore of vital importance. For instance, a report from the Office for National Statistics, a UK government department, reveals that as of July 2023, SMA, which affects between 1 in 10,000 and 20,000 live births with over 95% of sufferers being homozygous for SMN1 deletion, has been precisely recorded due to genetic testing of the SMN1 gene. As such, the increasing occurrence of rare genetic conditions is set to fuel the growth of the spinal muscular atrophy market.

What Segment Types Define the Spinal Muscular Atrophy Market Structure?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Spinal Muscular Atrophy Market?

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Spinal Muscular Atrophy Industry?

Notable businesses in the spinal muscular atrophy industry are working on the creation of novel items like dry syrup to provide better medication adherence and simplify administration for pediatric patients and others who find it challenging to swallow. Dry syrup refers to a powdery drug that is blended with water prior to consumption. This medication is primarily prescribed to infants and patients having trouble swallowing pills or capsules. In September 2024, for example, the Japan-centric pharmaceutical firm Chugai Pharmaceutical Co., Ltd. received authorization from the Ministry of Health, Labour and Welfare of Japan for its expanded drug indication, Evrysdi (risdiplam). This approval makes it possible for the drug to be used in unsymptomatic spinal muscular atrophy (SMA) cases and permits dosage to infants under two months old. This key development allows the commencement of treatment before the manifestation of symptoms, potentially boosting therapeutic results for affected babies. The approval was backed by findings from the RAINBOWFISH research which evaluated the safety and effectiveness of Evrysdi in infants diagnosed with SMA who do not have symptoms yet. Results indicated that the infants who received the treatment reached developmental milestones such as unsupported sitting and enhanced motor abilities by 12 months. This emphasizes the drug’s potential to alter the progression of this disease if given early.

View the full report here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

What Is the Definition of the Spinal Muscular Atrophy Market?

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive loss of motor neurons in the spinal cord, leading to muscle weakness and atrophy. It is caused by mutations in the SMN1 gene, resulting in insufficient survival motor neuron (SMN) protein. SMA affects voluntary muscle movements, particularly those involved in walking, swallowing, and breathing.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20965

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model